Dr. Bryan Mehlhaff on PSA's Role in Prostate Cancer

Bryan Mehlhaff, MD
Published: Monday, Nov 28, 2016


Bryan Mehlhaff, MD, medical director of research for Oregon Urology Institute, discusses the controversy surrounding prostate-specific antigen (PSA) testing in prostate cancer.
 
The United States Preventative Services Task Force gave PSA testing a grade ‘D’ recommendation in 2012 based on evidence regarding both the benefits and harms of the service and an assessment of the balance.
 
Since the D grade was announced a lot less screening has been conducted, says Mehlhaff, especially in men in their 50s or 60s. Mehlhaff believes this has lead to delayed diagnosis of prostate cancers and more men being diagnosed with advanced stage, hormone-sensitive prostate cancer.
SELECTED
LANGUAGE

Bryan Mehlhaff, MD, medical director of research for Oregon Urology Institute, discusses the controversy surrounding prostate-specific antigen (PSA) testing in prostate cancer.
 
The United States Preventative Services Task Force gave PSA testing a grade ‘D’ recommendation in 2012 based on evidence regarding both the benefits and harms of the service and an assessment of the balance.
 
Since the D grade was announced a lot less screening has been conducted, says Mehlhaff, especially in men in their 50s or 60s. Mehlhaff believes this has lead to delayed diagnosis of prostate cancers and more men being diagnosed with advanced stage, hormone-sensitive prostate cancer.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Archived Version of a Live Webcast: Virtual Current Trends™: European Perspectives on the Advancing Role of CAR T-Cell Therapy in Hematologic MalignanciesJun 29, 20192.0
Community Practice Connections™: Practical Application of Sequencing for EGFR-Mutant Lung Cancers: A Focus on Recent Evidence and Key Next Steps in TrialsJun 29, 20192.5
Publication Bottom Border
Border Publication
x